Developer docs
API playgroundTry for free, no card

Search company profiles

Ultragenyx Pharmaceutical

Full company profile

uuid0000dvt

Namestring
Ultragenyx Pharmaceutical
Legal namestring
Ultragenyx Pharmaceutical Inc.
Websiteurl
ultragenyx.com
Company typeenum
Public
Founded yearint
2010
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersNovato, United States
HQ citystring
Novato
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices23 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, gene therapy development, biopharmaceutical products, enzyme replacement therapy, AAV gene therapy
Industry2 codes
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAAAK
Therapeutic Enzymes & Enzyme Replacement Therapies (ERT)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Rare Disease Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales - Commercialized Therapies
TypeOne Time License
Description

Ultragenyx generates revenue from four approved products: Crysvita (burosumab), Dojolvi (triheptanoin), and additional rare disease therapies. The company reported Q1 2026 revenue of $136 million and reaffirmed 2026 revenue guidance of $730-760 million. Crysvita has surpassed $4 billion in US and Canada sales since launch.

seekingalpha.com
2Royalty Revenue
TypeLicensing Royalties
Description

The company receives royalty payments from partnered products including Kyowa Kirin's collaboration on Crysvita. In November 2025, Ultragenyx sold a 25% royalty interest on Crysvita to OMERS for $400 million, with additional royalties starting January 2028.

openpr.com
3Gene Therapy Development
TypeLicensing Royalties
Description

Revenue generated from development and potential approval of gene therapy candidates including UX111 (Sanfilippo syndrome), DTX401 (GSDIa), and DTX301 (OTC deficiency), with upcoming PDUFA dates in 2026.

ir.ultragenyx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ultragenyx Pharmaceutical develops and commercializes biologic and small-molecule therapeutics for rare and ultra-rare genetic diseases. The company's approved and clinical-stage portfolio spans multiple drug modalities, including AAV gene therapies, antisense oligonucleotides, monoclonal antibodies, enzyme replacement therapies, and substrate replacement therapies, sold globally through specialty pharmacies, hospitals, and regional commercial operations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 18% reduction in 24-hour plasma ammonia levels (p=0.018) in OTC deficiency patients treated with DTX301 gene therapy
+4 more records
Product overview1 text field

Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing and delivering treatments for rare and ultrarare genetic diseases. The company has a diversified pipeline spanning multiple drug modalities including gene therapies, monoclonal antibodies, and antisense oligonucleotides. Approved products include Crysvita (burosumab) for XLH and TIO. Key pipeline candidates include: gene therapies DTX401 (GSDIa, PDUFA Aug 2026), DTX301 (OTC deficiency), UX111 (MPS IIIA, PDUFA Sep 2026), and UX701 (Wilson disease); GTX-102 for Angelman syndrome (Phase 3); UX016 for GNE myopathy (Phase 1/2); and setrusumab for osteogenesis imperfecta. The company operates in multiple countries globally and is working toward profitability by 2027.

Product and service10 records
1Crysvita (Burosumab)
CategoryApproved biopharmaceutical product
Description

Crysvita is an approved monoclonal antibody therapy for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), rare bone diseases. Developed in collaboration with Kyowa Kirin, it has surpassed $4 billion in US and Canada sales since launch, with a 25% royalty interest sold to OMERS for $400 million in November 2025.

2Dojolvi (Triheptanoin)
CategoryApproved biopharmaceutical product
Description

Dojolvi (triheptanoin) is an approved Ultragenyx therapy for a rare metabolic disorder, part of the company's four-product commercial portfolio contributing to 2026 revenue guidance of $730–760 million.

3GTX-102
CategoryClinical-stage pipeline therapy
Description

GTX-102 is an antisense oligonucleotide therapy being developed for Angelman syndrome, a rare neurological disorder with no currently approved therapies. Phase 3 Aspire trial is ongoing with primary endpoint of cognition. Acquired through the July 2022 GeneTx Biotherapeutics acquisition for $75 million.

4UX111 (Rebisufligene Etisparvovec)
CategoryGene therapy - BLA stage
Description

UX111 (rebisufligene etisparvovec) is an adeno-associated virus (AAV9) gene therapy for Sanfilippo syndrome Type A (MPS IIIA), a rare neurodegenerative disease affecting young children. FDA accepted the BLA with a PDUFA action date of September 19, 2026, and clinical data spanning up to 8 years demonstrates durable treatment effect.

5DTX401
CategoryGene therapy - BLA stage
Description

DTX401 is an investigational AAV8 gene therapy for Glycogen Storage Disease Type Ia (GSDIa). Phase 3 GlucoGene study showed 60% reduction in daily cornstarch dependence while maintaining stable glucose levels. If approved, would be the first-ever gene therapy for GSDIa. PDUFA action date of August 23, 2026.

6DTX301
CategoryGene therapy - Phase 3
Description

DTX301 is an investigational AAV8 gene therapy for ornithine transcarbamylase (OTC) deficiency. Phase 3 Enh3ance study showed 18% reduction in 24-hour plasma ammonia versus placebo at Week 36 (p=0.018). Second primary endpoint evaluating treatment burden reduction is expected H1 2027.

7UX701
CategoryClinical-stage pipeline therapy
Description

UX701 is an investigational gene therapy for Wilson disease, a rare genetic disorder causing copper accumulation. Part of Ultragenyx's diverse pipeline targeting rare genetic diseases.

8UX143 (Setrusumab)
CategoryClinical-stage pipeline therapy
Description

UX143 (setrusumab) is a monoclonal antibody being developed for Osteogenesis Imperfecta. Phase 3 ORBIT and COSMIC studies failed to meet primary endpoints in December 2025. The company is pursuing an accelerated approval pathway based on bone mineral density data.

9UX016
CategoryClinical-stage pipeline therapy
Description

UX016 is an investigational sialic acid prodrug being developed as a substrate replacement therapy for GNE myopathy (GNEM), a rare, severely debilitating neuromuscular disorder affecting approximately 10,000 people in commercially accessible geographies. FDA cleared IND in March 2026 with a Phase 1/2 study planned for H2 2026 involving 24 US patients. The program is externally funded through a venture philanthropy agreement with a patient group.

10UX055
CategoryClinical-stage pipeline therapy
Description

UX055 is an investigational therapy for CDD (cerebellar degeneration) in Ultragenyx's pipeline for rare genetic diseases.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-03
Description

Potential merger between Ultragenyx and Mereo BioPharma was discussed, with a shareholder vote deadline of April 30, 2026. If approved, the merger could create a stronger biopharmaceutical company focused on rare diseases.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-30
Description

The UX016 program for GNE myopathy is externally funded through a venture philanthropy agreement with a patient group. This patient organization provides funding and support for the development of treatments for this rare neuromuscular disorder.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

Collaboration with Kyowa Kirin on Crysvita (burosumab), a treatment for rare bone diseases including X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). Crysvita has surpassed $4 billion in US and Canada sales since launch. The partnership involves co-development, co-promotion, and royalty arrangements.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-18
Description

Ultragenyx exercised its option to acquire GeneTx Biotherapeutics for $75 million to advance the development of GTX-102, an investigational therapy for Angelman syndrome. GeneTx was founded by the Foundation for Angelman Syndrome Therapeutics (FAST). The acquisition allows Ultragenyx to fully own and develop the Angelman syndrome treatment program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

FAST founded GeneTx Biotherapeutics, which Ultragenyx acquired for $75 million. FAST is a patient advocacy organization that drives research and development for Angelman syndrome treatments, working closely with Ultragenyx on the GTX-102 program.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ultragenyx Pharmaceutical

Rare Disease Biopharmaceuticalsultragenyx.com

Ultragenyx Pharmaceutical firmographics

Firmographics
Name
Ultragenyx Pharmaceutical
Legal name
Ultragenyx Pharmaceutical Inc.
Website
https://ultragenyx.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

Ultragenyx Pharmaceutical industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAAAK
Therapeutic Enzymes & Enzyme Replacement Therapies (ERT)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Rare disease therapeutics
  • Gene therapy development
  • Biopharmaceutical products
  • Enzyme replacement therapy
  • AAV gene therapy

Where Ultragenyx Pharmaceutical is headquartered

Location

Headquarters

HQ city
Novato
HQ country
United States
HQ region
North America

Offices23 records

Markets served

Ultragenyx Pharmaceutical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Product Sales - Commercialized Therapies: Ultragenyx generates revenue from four approved products: Crysvita (burosumab), Dojolvi (triheptanoin), and additional rare disease therapies. The company reported Q1 2026 revenue of $136 million and reaffirmed 2026 revenue guidance of $730-760 million. Crysvita has surpassed $4 billion in US and Canada sales since launch.
  2. Royalty Revenue: The company receives royalty payments from partnered products including Kyowa Kirin's collaboration on Crysvita. In November 2025, Ultragenyx sold a 25% royalty interest on Crysvita to OMERS for $400 million, with additional royalties starting January 2028.
  3. Gene Therapy Development: Revenue generated from development and potential approval of gene therapy candidates including UX111 (Sanfilippo syndrome), DTX401 (GSDIa), and DTX301 (OTC deficiency), with upcoming PDUFA dates in 2026.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Ultragenyx Pharmaceutical product offering

Product offering

Core offering

Ultragenyx Pharmaceutical develops and commercializes biologic and small-molecule therapeutics for rare and ultra-rare genetic diseases. The company's approved and clinical-stage portfolio spans multiple drug modalities, including AAV gene therapies, antisense oligonucleotides, monoclonal antibodies, enzyme replacement therapies, and substrate replacement therapies, sold globally through specialty pharmacies, hospitals, and regional commercial operations.

Product overview

Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing and delivering treatments for rare and ultrarare genetic diseases. The company has a diversified pipeline spanning multiple drug modalities including gene therapies, monoclonal antibodies, and antisense oligonucleotides. Approved products include Crysvita (burosumab) for XLH and TIO. Key pipeline candidates include: gene therapies DTX401 (GSDIa, PDUFA Aug 2026), DTX301 (OTC deficiency), UX111 (MPS IIIA, PDUFA Sep 2026), and UX701 (Wilson disease); GTX-102 for Angelman syndrome (Phase 3); UX016 for GNE myopathy (Phase 1/2); and setrusumab for osteogenesis imperfecta. The company operates in multiple countries globally and is working toward profitability by 2027.

Differentiator

Problem solved

Functional benefit

Products and services

  • Crysvita (Burosumab) Crysvita is an approved monoclonal antibody therapy for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), rare bone diseases. Developed in collaboration with Kyowa Kirin, it has surpassed $4 billion in US and Canada sales since launch, with a 25% royalty interest sold to OMERS for $400 million in November 2025.
  • Dojolvi (Triheptanoin) Dojolvi (triheptanoin) is an approved Ultragenyx therapy for a rare metabolic disorder, part of the company's four-product commercial portfolio contributing to 2026 revenue guidance of $730–760 million.
  • GTX-102 GTX-102 is an antisense oligonucleotide therapy being developed for Angelman syndrome, a rare neurological disorder with no currently approved therapies. Phase 3 Aspire trial is ongoing with primary endpoint of cognition. Acquired through the July 2022 GeneTx Biotherapeutics acquisition for $75 million.
  • UX111 (Rebisufligene Etisparvovec) UX111 (rebisufligene etisparvovec) is an adeno-associated virus (AAV9) gene therapy for Sanfilippo syndrome Type A (MPS IIIA), a rare neurodegenerative disease affecting young children. FDA accepted the BLA with a PDUFA action date of September 19, 2026, and clinical data spanning up to 8 years demonstrates durable treatment effect.
  • DTX401 DTX401 is an investigational AAV8 gene therapy for Glycogen Storage Disease Type Ia (GSDIa). Phase 3 GlucoGene study showed 60% reduction in daily cornstarch dependence while maintaining stable glucose levels. If approved, would be the first-ever gene therapy for GSDIa. PDUFA action date of August 23, 2026.
  • DTX301 DTX301 is an investigational AAV8 gene therapy for ornithine transcarbamylase (OTC) deficiency. Phase 3 Enh3ance study showed 18% reduction in 24-hour plasma ammonia versus placebo at Week 36 (p=0.018). Second primary endpoint evaluating treatment burden reduction is expected H1 2027.
  • UX701 UX701 is an investigational gene therapy for Wilson disease, a rare genetic disorder causing copper accumulation. Part of Ultragenyx's diverse pipeline targeting rare genetic diseases.
  • UX143 (Setrusumab) UX143 (setrusumab) is a monoclonal antibody being developed for Osteogenesis Imperfecta. Phase 3 ORBIT and COSMIC studies failed to meet primary endpoints in December 2025. The company is pursuing an accelerated approval pathway based on bone mineral density data.
  • UX016 UX016 is an investigational sialic acid prodrug being developed as a substrate replacement therapy for GNE myopathy (GNEM), a rare, severely debilitating neuromuscular disorder affecting approximately 10,000 people in commercially accessible geographies. FDA cleared IND in March 2026 with a Phase 1/2 study planned for H2 2026 involving 24 US patients. The program is externally funded through a venture philanthropy agreement with a patient group.
  • UX055 UX055 is an investigational therapy for CDD (cerebellar degeneration) in Ultragenyx's pipeline for rare genetic diseases.

Quantifiable outcome

  • 18% reduction in 24-hour plasma ammonia levels (p=0.018) in OTC deficiency patients treated with DTX301 gene therapy
  • +4 more outcomes

Companies that use Ultragenyx Pharmaceutical

Customer profile

Segments1 record

Ideal customer profiles2 records

Ultragenyx Pharmaceutical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Ultragenyx Pharmaceutical partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • Mereo BioPharmaminorStrategic or Co-development Partner · 3 April 2026Potential merger between Ultragenyx and Mereo BioPharma was discussed, with a shareholder vote deadline of April 30, 2026. If approved, the merger could create a stronger biopharmaceutical company focused on rare diseases.
  • Patient Advocacy Group (GNE Myopathy)minorStrategic or Co-development Partner · 30 March 2026The UX016 program for GNE myopathy is externally funded through a venture philanthropy agreement with a patient group. This patient organization provides funding and support for the development of treatments for this rare neuromuscular disorder.
  • Kyowa KirincoreStrategic or Co-development Partner · 4 November 2025Collaboration with Kyowa Kirin on Crysvita (burosumab), a treatment for rare bone diseases including X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). Crysvita has surpassed $4 billion in US and Canada sales since launch. The partnership involves co-development, co-promotion, and royalty arrangements.
  • GeneTx BiotherapeuticscoreStrategic or Co-development Partner · 18 July 2022Ultragenyx exercised its option to acquire GeneTx Biotherapeutics for $75 million to advance the development of GTX-102, an investigational therapy for Angelman syndrome. GeneTx was founded by the Foundation for Angelman Syndrome Therapeutics (FAST). The acquisition allows Ultragenyx to fully own and develop the Angelman syndrome treatment program.
  • Foundation for Angelman Syndrome Therapeutics (FAST)coreStrategic or Co-development PartnerFAST founded GeneTx Biotherapeutics, which Ultragenyx acquired for $75 million. FAST is a patient advocacy organization that drives research and development for Angelman syndrome treatments, working closely with Ultragenyx on the GTX-102 program.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Ultragenyx Pharmaceutical competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ultragenyx Pharmaceutical social profiles

Digital presence

Ultragenyx Pharmaceutical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ultragenyx Pharmaceutical leadership team

Management profile

Number of profiles

Profiles17 records

Ultragenyx Pharmaceutical subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Ultragenyx Pharmaceutical funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ultragenyx Pharmaceutical M&A and investment

M&A and investment

M&A2 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ultragenyx Pharmaceutical

What does Ultragenyx Pharmaceutical do?

Ultragenyx Pharmaceutical develops and commercializes biologic and small-molecule therapeutics for rare and ultra-rare genetic diseases. The company's approved and clinical-stage portfolio spans multiple drug modalities, including AAV gene therapies, antisense oligonucleotides, monoclonal antibodies, enzyme replacement therapies, and substrate replacement therapies, sold globally through specialty pharmacies, hospitals, and regional commercial operations.

Is Ultragenyx Pharmaceutical a public or private company?

Ultragenyx Pharmaceutical is a public company. It is classified as public and is currently operating.

When was Ultragenyx Pharmaceutical founded?

Ultragenyx Pharmaceutical was founded in 2010. It employs 1,001 to 5,000 people.

Where is Ultragenyx Pharmaceutical based?

Ultragenyx Pharmaceutical is headquartered in Novato, United States, in the North America region.

How does Ultragenyx Pharmaceutical make money?

Three revenue lines are on record. Product Sales - Commercialized Therapies are the primary driver. The others are royalty Revenue and gene Therapy Development.

Does Ultragenyx Pharmaceutical have an API?

No public API is recorded for Ultragenyx Pharmaceutical.

What industry is Ultragenyx Pharmaceutical in?

Ultragenyx Pharmaceutical's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAAAAAK, Therapeutic Enzymes & Enzyme Replacement Therapies (ERT). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsUltragenyx Pharmaceutical Inc. (RARE) – What Are Investment Firms Saying About This Stock?Ultragenyx Pharmaceutical received a consensus 'Hold' rating from 22 analysts, with an average 12-month target of $29.79. The company reported a quarterly loss of $1.16 per share, missing estimates, while revenue rose 8.2% to $173 million. Hedge funds and insiders have increased stakes, with 97.67% institutional ownership.Seeking AlphaUltragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 TranscriptUltragenyx CEO Emil Kakkis said the company expects to reach $1 billion in revenue and become profitable next year. He cited six approved products and ongoing programs, including imperfecta and setrusumab, despite recent misses.Business & FinancialUltragenyx To Participate At Investor Conferences In LondonUltragenyx executives Emil Kakkis, Eric Crombez, and Howard Horn will participate in fireside chats and host 1x1 meetings at the UBS Global Biopharma Conference on November 16 and the Jefferies Global Healthcare Conference on November 17, 2026, in London. The webcasts will be available on the company's website.GlobeNewswireUltragenyx to Participate at Investor Conferences in LondonUltragenyx Pharmaceutical announced its participation in the UBS Global Biopharma Conference on November 16 and the Jefferies Global Healthcare Conference on November 17, 2026. CEO Emil Kakkis, CMO Eric Crombez, and CFO Howard Horn will host fireside chats and 1x1 meetings, with webcasts available on the company's website.Stock TitanUltragenyx to Join Two Investor Conferences Nov. 16-17Ultragenyx Pharmaceutical will participate in the UBS Global Biopharma Conference on November 16 and the Jefferies Global Healthcare Conference on November 17. CEO Emil Kakkis, CMO Eric Crombez, and CFO Howard Horn will host fireside chats and 1x1 meetings, with webcasts available on the company's website.Simply Wall StUltragenyx Pharmaceutical (RARE) Could Be 38% Undervalued After UK UX111 Filing ProgressUltragenyx Pharmaceutical's UK MA application for UX111 gene therapy for Sanfilippo syndrome Type A was accepted, but the stock fell 39.91% over 90 days. The company trades below analyst targets, with a fair value of $26.00 versus a closing price of $16.14.FiercePharmaAgentic AI Is Rewriting The Pharma Marketing PlaybookAgentic AI is being used in pharma marketing to target small patient populations, with Sanofi developing a lab-in-a-loop and Ultragenyx's Crysvita requiring precision outreach. Early tests show marketing planning cycles collapsing by up to 10x, potentially making more treatments commercially viable.Defense WorldMorgan Stanley Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) StockMorgan Stanley raised its price target for Ultragenyx Pharmaceutical to $22 from $20, citing a potential upside of 41.30%. The company reported Q3 adjusted EPS of -$1.16, missing the -$1.10 consensus, though revenue rose 8.2% year over year. Analysts' consensus remains a Hold with a $29.79 target.Defense WorldUltragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, TD Cowen Analyst SaysTD Cowen raised its price target on Ultragenyx Pharmaceutical to $19 from $18, keeping a buy rating. The company's Q3 revenue of $173 million and adjusted EPS of -$1.16 missed analyst estimates, though revenue grew 8.2% year over year. Insiders sold 8,510 shares in the last 90 days.